PMPRB report reviews potential impact of new medicines on the Canadian market

Imported from official source

Announcement

Safety Classified by Officially

The Patented Medicine Prices Review Board published the 9th edition of its annual Meds Entry Watch report today.

June 17, 2025 — Ottawa, ON — Patented Medicine Prices Review Board

The Patented Medicine Prices Review Board (PMPRB) published the 9th edition of its annual Meds Entry Watch report today. Like last year, the analysis finds that the number of new medicines launched in Canada is higher than the median for Organisation for Economic Co-operation and Development (OECD) countries. Most new medicines come to market with high treatment costs (over $10,000 per year or $5,000 per 28-day cycle for oncology), and specialty medicines such as biologic, orphan, and cancer treatments continue to make up a growing share of the new drug landscape.

The Meds Entry Watch report focuses on medicines approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and/or Health Canada. This edition examines trends in the market for new medicines approved since 2018, highlighting the 48 medicines that received first-time market approval in 2022 and providing a preliminary analysis of the 63 medicines approved in 2023.

This publication informs decision makers, researchers, and patients of the evolving market dynamics of emerging therapies in Canadian and international pharmaceutical markets.

From 2018 to 2023, an average of 52 new medicines were approved internationally each year. Half of these medicines received an orphan designation from the FDA or EMA.

In 2023, 63 new medicines were approved by the FDA, the EMA, and/or Health Canada. 

Between 2019 and 2023, Health Canada approved 40 new medicines each year on average, of which 35% were expensive drugs for rare diseases.

This is an extract. The publication continues at the source.

Source: Patented Medicine Prices Review Board. Licence

Read the original at the source: https://www.canada.ca/en/patented-medicine-prices-review/news/2025/06/pmprb-report-reviews-potential-impact-of-new-medicines-on-the-canadian-market.html

Officially imported this from Patented Medicine Prices Review Board’s own source and shows an extract. If you work there, claiming the profile and verifying the domain lets you choose to show the full text here.

Provenance

Organization
Patented Medicine Prices Review Board — imported from official source
Official source
https://api.io.canada.ca/io-server/gc/news/en/v2?dept=patentedmedicinepricesreviewboard&sort=publishedDate&orderBy=desc&publishedDate%3E=2021-07-23&pick=50&format=atom&atomtitle=Patented%20Medicine%20Prices%20Review%20Board ATOM
Imported
October 03, 2026 20:43
Versions
1 recorded
Identity
https://www.canada.ca/en/patented-medicine-prices-review/news/2025/06/pmprb-report-revi...

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.